Opportunity Information: Apply for RFA AG 24 017
The National Institutes of Health (NIH) is offering a limited-competition renewal opportunity for the Longevity Consortium (LC) under the funding announcement titled "Limited Competition: Renewal of the Longevity Consortium (U19 Clinical Trial Not Allowed)." This opportunity is released as a discretionary grant program and uses a cooperative agreement mechanism, meaning the funded work will be carried out with substantial NIH program involvement compared with a typical research grant. The specific announcement number is RFA-AG-24-017, and it falls under the health-related funding activity area with CFDA number 93.866.
The Longevity Consortium itself was originally established in 2004 and is described as part of a broader set of ongoing translational efforts focused on human longevity. The consortium model supports coordinated, multi-project research aimed at identifying and moving toward translation of protective factors associated with exceptional longevity. In practical terms, the LC supports research approaches that may include genomic discovery and analysis, along with other biological or environmental factors that appear to contribute to unusually long and healthy lives. The central aim of this renewal is to continue and strengthen that collaborative infrastructure so investigators can further pinpoint protective mechanisms and set the stage for translating those insights into strategies relevant to aging and age-related health, while staying within the bounds of a program that does not support clinical trials.
The funding instrument is a U19 cooperative agreement, which is commonly used for complex, multi-component projects that benefit from coordinated management and shared cores or resources. The announcement explicitly states "Clinical Trial Not Allowed," which signals that applicants should not propose studies that meet the NIH definition of a clinical trial. Applicants should therefore frame the work as translational and human longevity-focused research without proposing interventional clinical trial designs, even if human data or human-derived samples and observational analyses are involved.
Eligibility information in the source data highlights small businesses as eligible applicants, but the announcement also includes important restrictions regarding foreign participation. Non-domestic (non-U.S.) entities (foreign institutions) are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are also not eligible to apply. At the same time, foreign components, as defined by the NIH Grants Policy Statement, are allowed, which typically means certain elements of the research can be conducted in collaboration with foreign sites or investigators when appropriately justified and structured under NIH policy, even though the primary applicant must be domestic and meet the stated eligibility requirements.
From a funding standpoint, the opportunity lists an award ceiling of $9,000,000. The original application closing date was February 2, 2024. The announcement was created on May 10, 2023. The expected number of awards is not clearly specified in the provided source text, but the limited-competition framing suggests it may be restricted to a defined group of eligible applicants, often tied to existing program participation or specific renewal eligibility conditions described in the full announcement.
Overall, this NOFO is designed to renew a long-running NIH-supported consortium dedicated to uncovering the protective genomic and related factors linked to exceptional longevity, with an emphasis on coordinated translational research conducted through a U19 cooperative agreement structure, and with clear limitations on clinical trial activity and foreign institutional eligibility.Apply for RFA AG 24 017
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition: Renewal of the Longevity Consortium (U19 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2023-05-10.
- Applicants must submit their applications by 2024-02-02. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $9,000,000.00 in funding.
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the funding opportunity title and purpose?
The opportunity is titled "Limited Competition: Renewal of the Longevity Consortium (U19 Clinical Trial Not Allowed)." Its purpose is to renew and strengthen the Longevity Consortium (LC), a coordinated, multi-project research effort focused on understanding exceptional human longevity and identifying protective factors that may be translated into strategies relevant to aging and age-related health.
Which agency is offering this opportunity?
This opportunity is offered by the National Institutes of Health (NIH).
What is the announcement number for this NOFO?
The announcement number is RFA-AG-24-017.
What type of funding mechanism is being used?
The mechanism is a U19 cooperative agreement. This is typically used for complex, multi-component projects that benefit from coordinated management and shared infrastructure (for example, multiple projects supported by shared cores or resources).
What does "cooperative agreement" mean in practical terms?
A cooperative agreement means the funded work will be carried out with substantial NIH program involvement compared with a typical research grant. In other words, NIH is expected to have an active role in program coordination and oversight consistent with a cooperative agreement structure.
Is this a discretionary grant program?
Yes. The opportunity is described as a discretionary grant program.
What does "Limited Competition" mean for applicants?
"Limited Competition" indicates the renewal is likely restricted to a defined group of eligible applicants, often tied to existing program participation or specific renewal eligibility conditions described in the full announcement. The provided information does not list the exact group, but it does emphasize that the competition is not fully open.
What is the Longevity Consortium (LC)?
The Longevity Consortium is an NIH-supported consortium originally established in 2004 as part of broader translational efforts focused on human longevity. It supports coordinated, multi-project research aimed at identifying protective factors associated with exceptional longevity and moving those insights toward translation.
What kinds of scientific approaches does the LC support?
The LC supports research approaches that may include genomic discovery and analysis, along with investigation of other biological or environmental factors that appear to contribute to unusually long and healthy lives. The emphasis is on coordinated translational research rather than isolated single-project studies.
What is the main goal of this renewal?
The central goal is to continue and strengthen the collaborative consortium infrastructure so investigators can further pinpoint protective mechanisms linked to exceptional longevity and set the stage for translation into strategies relevant to aging and age-related health.
Are clinical trials allowed under this opportunity?
No. The announcement explicitly states "Clinical Trial Not Allowed." Applicants should not propose studies that meet the NIH definition of a clinical trial.
If clinical trials are not allowed, can the project still include research involving humans?
Yes, the research can be framed as translational and human longevity-focused without proposing interventional clinical trial designs. Human data, human-derived samples, and observational analyses may be involved, as long as the proposed work does not meet the NIH definition of a clinical trial.
What is the CFDA number and funding activity area associated with this opportunity?
The opportunity is in a health-related funding activity area and lists CFDA number 93.866.
Who is eligible to apply based on the information provided?
The source information highlights small businesses as eligible applicants. The opportunity also includes restrictions related to foreign participation (see related questions below).
Can a foreign (non-U.S.) institution apply as the primary applicant?
No. Non-domestic (non-U.S.) entities (foreign institutions) are not eligible to apply as the applicant organization.
Can a non-domestic component of a U.S. organization apply?
No. Non-domestic components of U.S. organizations are also not eligible to apply as the applicant organization.
Are foreign components allowed at all?
Yes. Foreign components, as defined by the NIH Grants Policy Statement, are allowed. This typically means certain elements of the research can be conducted in collaboration with foreign sites or investigators when appropriately justified and structured under NIH policy, even though the primary applicant must be domestic and meet stated eligibility requirements.
What is the maximum award amount listed for this opportunity?
The listed award ceiling is $9,000,000.
When was the funding announcement created?
The announcement was created on May 10, 2023.
What was the application closing date mentioned in the provided information?
The original application closing date was February 2, 2024.
How many awards does NIH expect to make?
The expected number of awards is not clearly specified in the provided source text.
What is the overall research focus of the renewed consortium?
The overall focus is uncovering protective genomic and related factors linked to exceptional longevity, using coordinated translational research within a consortium model and staying within the "no clinical trials" limitation.
Browse more opportunities from the same category: Health
Next opportunity: NIH-DoD-VA Pain Management Collaboratory ? Pragmatic and/or Implementation Science Demonstration Projects ((UG3/UH3) Clinical Trial Required)
Previous opportunity: F23AS00319 FY2023 Implementation of the Quagga and Zebra Mussel Action Plan (QZAP) in the Western United States
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 24 017
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 24 017) also looked into and applied for these:
| Funding Opportunity |
|---|
| Aging Research Dissertation Awards to Promote Diversity (R36 Clinical Trial Not Allowed) Apply for PAR 23 174 Funding Number: PAR 23 174 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed) Apply for PAR 23 177 Funding Number: PAR 23 177 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| HIV Prevention and Alcohol (R01 Clinical Trials Optional) Apply for PAS 23 173 Funding Number: PAS 23 173 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV Prevention and Alcohol (R34 Clinical Trials Optional) Apply for PAS 23 172 Funding Number: PAS 23 172 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol Health Services Research (R01 Clinical Trial Optional) Apply for PAR 23 185 Funding Number: PAR 23 185 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol Health Services Research (R34 Clinical Trial Optional) Apply for PAR 23 186 Funding Number: PAR 23 186 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol Treatment and Recovery Research (R01 Clinical Trial Required) Apply for PAR 23 187 Funding Number: PAR 23 187 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed) Apply for RFA NS 24 010 Funding Number: RFA NS 24 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol Treatment and Recovery Research (R34 Clinical Trial required) Apply for PAR 23 188 Funding Number: PAR 23 188 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Analyzing Early Events in TB and TB/HIV Infection for Interventional Targets (R01 Clinical Trial Not Allowed) Apply for RFA AI 23 029 Funding Number: RFA AI 23 029 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Collaborative Opportunities for Multidisciplinary, Bold, and Innovative Neuroscience (COMBINE) (RM1 Clinical Trial Optional) Apply for RFA NS 23 027 Funding Number: RFA NS 23 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding Gene-Environment Interactions in Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Not Allowed) Apply for RFA AG 24 021 Funding Number: RFA AG 24 021 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Bioinformatics Resource Centers (BRCs) for Infectious Diseases (U24 Clinical Trials Not Allowed) Apply for RFA AI 23 032 Funding Number: RFA AI 23 032 Agency: National Institutes of Health Category: Health Funding Amount: $2,500,000 |
| Preclinical Studies to Characterize the Impact of Toxicants on Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Not Allowed) Apply for RFA AG 24 023 Funding Number: RFA AG 24 023 Agency: National Institutes of Health Category: Health Funding Amount: $1,250,000 |
| Quantifying the Impact of Environmental Toxicants on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Risk in Cohort Studies (U01 Clinical Trial Not Allowed) Apply for RFA AG 24 022 Funding Number: RFA AG 24 022 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Significance of Clonal Hematopoiesis (CH) in Aging Humans (R01 Clinical Trial Not Allowed)? Apply for RFA AG 24 038 Funding Number: RFA AG 24 038 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Measuring Financial Hardship Among People and Families Living with AD/ADRD (R01 Clinical Trial Not Allowed)? Apply for RFA AG 24 036 Funding Number: RFA AG 24 036 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Health Information Systems (HIS) Activity Apply for 72052123RFI00001 Funding Number: 72052123RFI00001 Agency: Haiti USAID-Port Au Prince Category: Health Funding Amount: Case Dependent |
| Assessment of TBI-related ADRD Pathology Related to Cognitive Impairment and Dementia Outcomes (U01 - Clinical Trial Not Allowed) Apply for RFA NS 24 003 Funding Number: RFA NS 24 003 Agency: National Institutes of Health Category: Health Funding Amount: $1,300,000 |
| Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed) Apply for PAR 23 211 Funding Number: PAR 23 211 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 24 017", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.